Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Craig Tooman has been appointed as chief financial officer at Silence Therapeutics, a biotechnology company that develops gene therapeutic technology based on RNA interference.
Tooman has also become a member of the executive leadership team, effective immediately. His career in the biopharmaceutical industry spans more than 30 years, including 15 years of experience as a public company CFO.
Most recently, he was CFO and chief operating officer at Vyome Therapeutics, and prior to this was CFO and then CEO of Aratana Therapeutics where he successfully negotiated a merger with Elanco. Before Aratana, Tooman was the CFO of Enzon Pharmaceuticals until its acquisition by Sigma Tau, and prior to that led the $1.1 billion M&A initiative and integration of ILEX Oncology and Genzyme Corporation.
Mark Rothera, president and CEO of Silence Therapeutics, said Tooman brings a deep understanding of financial strategy, US capital markets and business development and added: 'His appointment comes at a time of significant opportunity and growth, highlighted by the advancement of our two wholly owned product candidates into the clinic and three anticipated clinical data readouts this year. His business and financial expertise will be instrumental in helping us build our US footprint and positioning Silence as a leading global RNAi business.'
Incoming CFO Tooman said: ' Silence is a fast-growing company with ground-breaking technology that stands out in the RNAi space. It is exciting to join at this stage of the company's journey, following a number of recent successful partnerships and transformational deals.'
At 9:23am: (LON:SLN) Silence Therapeutics PLC share price was 0p at 455p